title: [A case of primary adenocarcinoma of small intestine responding to XELOX chemotherapy and leading to a partial metabolic response].
abstract: We report a case of adenocarcinoma of the small intestine responding to XELOX chemotherapy, leading to a partial metabolic response(PMR). The patient was a 58-year-old male with multiple peritoneal dissemination of adenocarcinoma of the small intestine. Chemotherapy with XELOX(L-OHP 130 mg/m² on day 1 , and capecitabine 1,000 mg/m2 on days 1-14)was performed. After 4 courses, a significant tumor reduction was obtained. This case suggests that chemotherapy with XELOX is a potential regimen for small intestinal adenocarcinoma.
authors.affiliation: Department of Surgery, Tottori Municipal Hospital.
authors.forename: Ken
authors.initials: K
authors.lastname: Seshimo
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Toshima
authors.forename: Kenji
authors.initials: K
authors.lastname: Mizuno
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ikeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kato
authors.forename: Masao
authors.initials: M
authors.lastname: Yamamura
authors.forename: Masahito
authors.initials: M
authors.lastname: Kodera
authors.forename: Masahiro
authors.initials: M
authors.lastname: Oishi
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yamashita
authors.forename: Noriaki
authors.initials: N
authors.lastname: Tanaka
authors.forename: Hiraku
authors.initials: H
authors.lastname: Fujita
authors.forename: Koutaro
authors.initials: K
authors.lastname: Shibagaki
authors.forename: Hideaki
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Hiromasa
authors.initials: H
authors.lastname: Takeda
authors.forename: Keita
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Keiko
authors.initials: K
authors.lastname: Takita
authors.forename: Manabu
authors.initials: M
authors.lastname: Nishie
authors.forename: Kazuhide
authors.initials: K
authors.lastname: Iwakawa
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000378:metabolism; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007078:Ileal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D010071:Oxaloacetates; D049268:Positron-Emission Tomography; D014057:Tomography, X-Ray Computed
chemical_list: D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D005472:Fluorouracil